Attention, memory, and executive functions profile in a prospective cohort of patients with malignant glioma. Issue 2 (4th March 2021)

• Record Type: Journal Article
• Authors: Loaiza, Sergio; Giraldo, Daniel; Galvis, Astrid; Ortiz, Leon; Carvajal, Sonia
• Is Part Of: Applied neuropsychology. Volume 28:Issue 2(2021)
• Page Start: 197
• Page End: 209
• Publication Date: 2021-03-04
• Subjects: Bayesian inference -- cognitive dysfunction -- malignant glioma -- temporal lobe -- verbal fluency; Neuropsychology -- Periodicals; Cognition disorders -- Periodicals; Brain -- Diseases -- Diagnosis -- Periodicals; Brain -- Imaging -- Periodicals; Brain -- Diseases -- Treatment -- Periodicals; Diagnostic Imaging -- Periodicals; Neuropsychological Tests -- Periodicals; Adult; 616.8
• DOI: 10.1080/23279095.2019.1621315
• Languages: English
• ISSNs: 2327-9095

Abstract

Abstract: A prospective cohort study was structured to examine patient's tumor mass factors that could determine a specific cognitive function profile in patients with Malignant Glioma who survived after the Stupp protocol, while adjusting for previously explored confounding factors. Neuropsi - Attention and Memory (Second edition) was applied after tumor resection, but before any other oncological treatment. Follow-up neuropsychological evaluation was conducted when patients completed the Stupp protocol treatment scheme. To estimate the mean difference between follow-up and baseline Neuropsi subtest scores, a Bayesian Mixed Effects Model was fitted with three random-effect regressors representing tumor locations, co-administered medications and by-patient cognitive performance variability. Sixteen patients were included. Temporal lobe tumors were the most frequent (31.2%) and more than three-fourths of those were located in the left lobe; such results agree with the clinical and statistical significance that supports an impairment in the Semantic Verbal Fluency subtest (Mean score change = −5.97, 95% Credible Interval = [−8.01, −3.80]). The findings suggest that any potential variants in a determined cognitive dysfunction profile could be more influenced by tumor location than any other variable related to the patient's tumor mass or administered oncological medications; however, because the limited sample representativeness, additional studies are required.